Safety Study of PP-007 in Acute Ischemic Stroke

This study is exploring the safety of a drug called PP-007 for people who have had an Acute Ischemic Stroke (AIS), which is when a blood clot blocks blood flow to the brain. Participants will receive two doses of PP-007, along with the usual care they would get for their stroke. PP-007 is a special form of a protein called carboxyhemoglobin that is delivered through an IV infusion (a needle placed into a vein). Researchers will look at how the drug affects blood flow in the brain and the size of the area affected by the stroke. They will also check if participants recover better with this treatment.

• Participants must be 18 years or older and able to attend follow-up visits.
• Study involves two infusions of PP-007, 24 hours apart, in addition to standard stroke care.
• Participants should use effective birth control during and up to 90 days after the study.

This study may help improve stroke treatments, but it’s important to understand the eligibility criteria and follow the doctor's advice carefully.